Skip to main content
. Author manuscript; available in PMC: 2014 Apr 22.
Published in final edited form as: Cancer Res. 2012 Nov 19;73(2):834–843. doi: 10.1158/0008-5472.CAN-12-2066

Figure 3. IGFBP3 is downregulated in PFR and WZR cells.

Figure 3

A. (Left) Comparison of expression profiles of PC9 and PFR3 cells (left panel). Hierarchical clustering of the differentially expressed genes (p<0.0025, fold change (FC) >3.9) was performed using GENE-E. (Right) The indicated cell lines were treated with either PF299804 (1 μM) alone, WZ4002 alone (1 μM) or in combination with BMS536924 (1 μM) for 6 hours. Cell extracts were immunoblotted to detect the indicated proteins. B. PFR3 cells were treated with increasing concentrations of PF299804 alone or in combination with IGFBP3. Viable cells were measured after 72 hours of treatment and plotted relative to untreated controls. C. PFR3or WZR4 cells were treated with PF299804 (1 μM) alone or in combination with IGBP3 (1 μg/mL). Colonies were counted after 14 days of treatment. D. PFR3 cells were treated with PF299804 (1 μM) alone, IGFBP3 alone (1 μg/mL) or with both agents for 6 hours. Cell extracts were immunoblotted to detect the indicated proteins.